Chief Financial Officer
Dana McGowan is the Chief Financial Officer at ARS Pharmaceuticals, Inc. She brings extensive financial experience in the biotechnology and high technology industries that spans fundraising, investor relations, financial strategy and financial operations.
Ms. McGowan provides financial consulting services as acting Chief Financial Officer for clinical-stage biotechnology companies Antiva Biosciences, Inc. and Lyric Pharmaceuticals, Inc. Previously, Ms. McGowan was Chief Financial Officer for Ocera Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on gastrointestinal and liver disease. Before that, she served as Vice President of Finance and Administration and Chief Financial Officer for MedVantx, a healthcare technology company, Kinzan, Inc., an internet company, and DepoTech Corporation, a public drug delivery company. Ms. McGowan has also held various financial positions with Cytel Corporation, a public biotechnology company focused on immunology and carbohydrates, and SAIC, a Fortune 500 technical services company. Her financial experience includes venture and debt financing, IPOs and follow-on offerings, corporate partnering and mergers and acquisitions.
Ms. McGowan holds a Bachelor of.Science in business administration from San Diego State University and is a certified public accountant (inactive). She has been a Springboard Panel Member for UCSD Connect, a donation and flexible event chair for Teen Volunteers in Action and is a former member of the CFO Steering Committee of UCSD Connect/Athena.